When to contact your GP, diabetes team, or healthcare professional: Severe or persistent nausea and vomiting preventing adequate fluid or food intake Signs of dehydration (dark urine, dizziness, reduced urination) Severe abdominal pain, particularly if accompanied by vomiting, or right upper abdominal pain with fever Symptoms of hypoglycaemia that don't resolve with usual treatment Unexplained weight loss exceeding clinical targets Changes in mood or suicidal thoughts Any concerns about medication tolerance or effectiveness The MHRA continues to monitor the safety profile of incretin medications through the Yellow Card scheme
Elithair works with the DHI and FUE methods and complements them with NEO FUE
Kristensen, M., & Holst, J
A case of acne fulminans with sacroiliitis successfully treated with methotrexate and isotretinoin
In agreement with published data, these cells were hardly sensitive to FA when compared to the isogenic cell line expressing a wild type copy of FANCD2 (PD20-wtD2) 39 (Fig
event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
